biotech / news / / Livemint
Tecentriq SC is now available across India with more than 100 patients already on immunotherapy.
Tecentriq SC, a subcutaneous lung cancer therapy, is now available across India after DCGI approval.
KEY POINTS
- The subcutaneous injection reduces administration time by 80%, allowing treatment in about seven minutes.
- Tecentriq SC's maximum retail price is ₹3.7 lakh per unit, higher than its IV version.
- Global clinical data shows 80% of patients preferred the subcutaneous version for comfort and reduced distress.
- If patients respond exceptionally well, Tecentriq SC therapy can be paused while patients remain stable.
COMPANIES
Summarized by Newsio from Livemint. How we summarize →